Equities research analysts expect Agile Therapeutics Inc (NASDAQ:AGRX) to report earnings per share of ($0.15) for the current quarter, Zacks reports. Zero analysts have made estimates for Agile Therapeutics’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.17). Agile Therapeutics reported earnings of ($0.22) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 31.8%. The business is scheduled to report its next quarterly earnings results on Monday, November 5th.
According to Zacks, analysts expect that Agile Therapeutics will report full-year earnings of ($0.60) per share for the current fiscal year, with EPS estimates ranging from ($0.63) to ($0.56). For the next year, analysts anticipate that the firm will post earnings of ($0.64) per share, with EPS estimates ranging from ($0.94) to ($0.41). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01.
In other news, insider Life Sciences Maste Perceptive sold 298,628 shares of the firm’s stock in a transaction dated Thursday, July 26th. The shares were sold at an average price of $0.30, for a total transaction of $89,588.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.30% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the stock. A.R.T. Advisors LLC lifted its holdings in Agile Therapeutics by 82.3% during the 1st quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after purchasing an additional 29,995 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Agile Therapeutics by 76.3% during the 2nd quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after purchasing an additional 343,290 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Agile Therapeutics by 62.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 55,937 shares during the last quarter. 52.00% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:AGRX opened at $0.81 on Tuesday. The stock has a market cap of $32.84 million, a PE ratio of -0.89 and a beta of 1.43. Agile Therapeutics has a 52 week low of $0.23 and a 52 week high of $5.33.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Read More: What is the Dividend Aristocrat Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.